Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

CMT-dos > Platelet and Bleeding disorders > Flashcards

Platelet and Bleeding disorders Flashcards

1
Q

Screening for Hemostasis

Primary vs Secondary Hemostasis

A

Primary Hemostasis (“Bruising”)
1) Bleeding time: Tests quality and quantity of platelet function
2) Platelet count

Secondary Hemostasis (“Bleeding”)
3) PT (Prothrombin Time)
Tests function of Extrinsic arm of clotting cascade
4) aPTT (activated Partial Thromboplastin Time)
Tests function of Intrinsic arm of clotting cascade

Bruising Disorders
Usually associated with platelet problems
Bleeding Disorders
Usually associated with coagulation problems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Symptoms Associated with Platelet Disorders

A

Easy Bruising
Slow, minor bleeding
Bleeding brushing teeth
Menorrhagia
Epistaxis
Petechial rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

platelet disorders

Thrombocytopenia

A

MOST common symptom is easy bruising and minor bleeding assoc. with minor trauma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

causes of decreased platelet production

A

Viral infections
HIV, Rubella
Marrow infiltration
Chemotherapy
Vitamin deficiency
B12, Folic Acid
Congenital Defects
Fanconi anemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Increased platelet destruction causes

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Thrombocytopenia of SEQUESTRATION

A
  • Splenomegaly causes an increase in splenic platelet pool and corresponding decrease in peripheral platelet count
  • Most commonly seen in congestive splenomegaly assoc with chronic liver disease
  • May also occur in other disorders characterized by large spleen (including lymphoma, myelofibrosis)
  • Mild anemia or leukopenia may also be seen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

immune thrombocytopenic purpura ITP

general

A

Autoimmune condition resulting in premature destruction of Platelets

Site of destruction
Spleen
Liver
Bone marrow (less common)
Diagnosis of exclusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

ITP

S/Sx

A

Mucosal bleeding
Epistaxis
Heavy menses
Purpura
Petechiae

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ITP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ITP

Laboratory findings

A

Isolated thrombocytopenia
Anemia, if significant bleeding
Abnormalities in platelet size and morphology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ITP

Bone Marrow Biopsy Indications

A

Atypical clinical symptoms
Malaise
Lymphadenopathy
Hepatosplenomegaly
Anemia/Leukopenia

**Age **
Age >60 yrs
MDS
Children
Leukemia
Refractory ITP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ITP

Tx

A

Platelet count >25,000/mcL close observation

Treatment needed if platelet count ≤ 25,000/mcL or significant bleeding

Steroids usual first line treatment
Prednisone with slow steroid taper
Response within 3-7 days but relapse is common during taper
Rituximab (Rituxan)
Intravenous Immunoglobulins
Rapid increase in platelets
Mechanism unknown
Splenectomy
>80% response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pseudothrombocytopenia

general

A

Low platelet count due to laboratory artifact

Incompletely mixed or inadequately anticoagulated sample may form clot
Traps platelets in the tube and prevents from being counted
0.1% of population EDTA anticoagulant induces platelet clumping
Platelet autoantibody against concealed epitope on platelet membrane glycoprotein IIb/IIIa
Repeat blood draw with heparin or sodium citrate as anticoagulant
Platelet clumping should not occur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

THROMBOTIC Microangiopathies“TMA”

includes and hallmarks of disease

A

Thrombotic thrombocytopenic purpura (TTP)
Hemolytic uremic syndrome (HUS)

Hallmarks of Disease:
Microangiopathic Hemolytic Anemia (MAHA)
Thrombocytopenia with THROMBOSES

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

THROMBOTIC Microangiopathies “TMA”

Pentad

A

Thrombocytopenia
Microangiopathic hemolytic anemia
Renal failure
Neurologic abnormalities
Fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

TMA (TTP and HUS)

Lab features

A

Anemia
1/3 patients < 6 g/dl
Thrombocytopenia
1/3 patients < 20,000/µL
Reticulocyte count UP
Lactate dehydrogenase (LDH) UP
Haptoglobin DOWN
Coomb’s test usually negative
Fibrinogen normal
Prothrombin time normal
Activated partial thromboplastin time normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

TMA

TTP Specific Dx

A

TTP:
ADAMTS13 activity levels
Anti-ADAMTS13 autoantibodies
Acquired TTP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

TTP Thrombotic Thrombocytopenic Purpura

general

A

Deficiency in ADAMTS13 activity
Pregnancy
Antibody-mediated
Adults
Rare
95% mortality rate if untreated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

HUS

Clinical Presentation
Types

A

Presents same as TTP EXCEPT:
Not associated w/ ADAMTS13 deficiency

2 types
* Completement Mediated HUS
* Shiga Toxin Mediated HUS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Shiga Toxin Mediated HUS

causes

A

May follow:
Viral infection
Diarrheal illness
E Coli O157:H7
Shigella dysenteriae
Exposure to
Farm animals
Undercooked meat
Contaminated water
Most common TMA in children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Complement Mediated HUS

general

A

Hereditary deficiency/abnormality of proteins leading to unregulated complement activation on cell membranes

Acquired form with Complement H factor
Leads to damage of endothelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

TMA

Tx

A

Plasmapheresis for TTP
FFP Transfusion
Steroids

Second line
Rituximab
IVIG
Corticosteroids
**Avoid platelet transfusions!
Worsens TMA

Hematology consultation
Plasmapheresis
Complement mediated HUS
Eculizumab (Soliris) infusion
Anti-complement C5 antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Heparin Induced thrombocytopenia “HIT”

General

A

Acquired disorder
Formation of IgG antibodies to heparin-platelet 4 (PF4) complexes
Bind to and activates platelets
3% of unfractionated heparin patients
0.6% low-molecular-weight heparin (LMWH) patients

HAD to have had a heparin product previously, this reaction is due to a secondary exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

HIT

RF

A

Prior heparin use
Long duration of heparin use
Surgery
Pregnancy
Trauma
Inflammatory conditions

27
Q

HIT

SSx

A

Typically asymptomatic
Arterial or venous thrombosis
Up to 30 days after diagnosis
Bleeding is rare

28
Q

Hit (heparin induced thrombocytopenia)

Dx

A

PF4 heparin antibody testing
Not many places do in house testing of this!
Takes a few days to get results back

29
Q

HIT

Tx

A

Consult hematology

Discontinue all heparin products immediately!
Hint: Unfractionated heparin (UFH) is commonly used to flush catheters

Platelet transfusions may increase thrombogenic effect
High risk for thrombotic events
Should be treated with alternative anticoagulants
Initiation of warfarin should be postponed until substantial platelet recovery

30
Q

HIT

Anticoagulation options

A

Argatroban weight-based infusion
Direct thrombin inhibitor
Fondaparinux (Arixtra) weight-based once daily injection
Factor Xa inhibitor
Prophylactic anticoagulation should continue until platelets >100,000/mcL
Continue for 30 days
Thrombosis treatment can be changed to warfarin after platelets >100,00/mcL
DOAC (direct oral anticoagulant) use not standard yet

31
Q
A
32
Q

HIT

Long term Tx

A

Avoid heparin exposure
Document history of HIT in allergies
If heparin products necessary, consult hematology
Will need repeat PF4 antibody levels drawn

33
Q

Disseminated intravascular coagulation (DIC)

general

A

Uncontrolled activation of coagulation leading to depletion of coagulation factors and fibrinogen

  • Procoagulant substances trigger systemic activation of the coagulation system and platelets
  • Disseminated deposition of fibrin-platelet thrombi within the microvasculature

Associated with
Sepsis
Burns
Head trauma
Pregnancy
HELLP syndrome

typically already a very sick patient

34
Q

DIC

S/Sx

A

Hallmark is:
Bleeding
Spontaneous bleeding
IV lines
Incisions
Minor trauma

Progressive thrombocytopenia

Thrombosis:
DVT
Digital ischemia
Gangrene

35
Q

DIC

lab features

A

Progressive thrombocytopenia
Fibrinogen DOWN
Fibrin degradation products UP
Platelets DOWN
PT / INR UP
PTT normal to UP
D-dimer UP
Peripheral smear
Schistocytes

36
Q

DIC

TX

A

treat underlying condition

HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) in pregnancy
Delivery of fetus
Removal of retained placenta

Give Blood products and factor replacement

37
Q

Hemophilia

general

A

bleeding disorder, not platelet disorder
X-linked recessive disorders
Spontaneous cases possible
Hemophilia A– Inherited deficiency of factor VIII
Hemophilia B– Inherited deficiency of factor IX
Hemophilia C – Inherited deficiency of factor XI

38
Q

Hemophilia A

general

A

X-linked recessive hereditary disorder of Factor VIII deficiency
2nd most common congenital bleeding disorder
Males almost exclusively affected

Severe = < 1% Factor VIII
Moderate = 1-5% Factor VIII
Mild = > 5% Factor VIII

Inherited deficiency of factor VIII
Males almost exclusively affected
1:4000 births
> ½ with severe disease
Hemophilia A more severe bleeding than B (IX)

39
Q

Hemophilia A

Clin Man

A

Spontaneous hemorrhage is hallmark of disease
Hemarthroses- 80% of hemorrhagic cases- bleeding into the joint capsule.
Muscle bleeds
GI bleeds
Bleeding tendency—related to severity of deficiency
Older Hemophiliacs may be HIV + due to historically contaminated Factor VIII blood

40
Q

hemophilia A

A

Hemarthrosis

41
Q

hemophilia A

Labs

A

Laboratory evaluation
Deficient Factor VIII
Prolonged aPTT
Should correct if perform a mixing study
If this does not correct, suggests acquired factor inhibitor

42
Q

hemophilia A

Tx

A

Factor VIII concentrate infusion

Recombinant Factor VIII (no HIV risk)
Calculation of Factor VIII dosage related to severity of bleeding. Failure to respond to Factor VIII suggest inhibitor production

Desmopressin may be effective in mild cases (vWF release, carrier of Factor VIII)
Prophylaxis

Emicizumab (Hemlibra) infusion
Monoclonal antibody that binds to both factor IXa and factor X, substituting for the role of factor VIII in hemostasis

AVOID Aspirin!

43
Q

Hemophilia B

general and Tx

A

Deficiency Factor IX
1:15,000 to 1:30,000 births
> 1/3 with severe disease
Presents clinically the same as Hemophilia A

Treatment
Factor IX concentrate replacement

44
Q

Hemophilia B:

Late complications

A

Hemophilic arthropathy
Infections from plasma products
1970s and 1980s
HIV
50%
Hepatitis C
Most patients
Family & pregnancy planning
Cardiovascular disease

45
Q

Hemophilia C

general and Tx

A

Deficiency Factor XI
1:1,000,000 births
Ashkenazi and Iraqi Jews
1:450
Bleeding is variable
Usually no spontaneous bleeding
PTT prolonged in severe deficiency (Factor < 20%)

Treatment
Factor XI replacement

46
Q

Von Willebrand Disease

general and types (3)

A

Most common inherited bleeding disorder

47
Q

VWD

S/Sx

A

Symptoms:
Type dependent, usually mild
Epistaxis
Easy bruising
Bleeding gums
Heavy menses

Symptoms can range from mild or infrequent bleeding in type 1 VWD to severe, life-threatening bleeding in type 3 VWD

  • Mucocutaneous bleeding symptoms
    Easy bruising
    Prolonged or excessive bleeding from minor injuries
    Nosebleeds
    GI hemorrhage
    Heavy menstrual bleeding
  • Risk for bleeding following :
    Surgery or invasive procedures,
    Dental extractions
    Traumatic injury
    Childbirth
48
Q

VWD

dont worry about specifics, but helpful!

A
49
Q

VWD

Lab results

A

Platelet count: normal
vWF levels: DOWN or dysfunctional
Bleeding time: typically UP
aPTT: often normal
May be UP if deficiency of Factor VIII

50
Q

VWD

Tx
Prophylaxis

A

Prophylaxis
DDAVP (synthetic vasopressin)
Promotes release of vWF from endothelial cells

Replacement therapy
vWF concentrate
Factor VIII concentrate in some patients

51
Q

Bleeding due to liver disease

clotting factors

Which are k dependent

A

Liver synthesizes and clears both procoagulants and inhibitors
The hepatocyte is the production site of almost all numbered coagulation factors including fibrinogen (factor I), thrombin (factor II), and upstream factors V, VII, IX, X, and XI

Exceptions
Factor VIII, which is produced in endothelial cells
Factor XIII A-subunit, which is produced in megakaryocytes

Fibrinogen the last to fall

If concurrent Vitamin K deficiency (alcohol use), Affects ALL vitamin K dependent factors (X, IX, VII, and II “1972”)

52
Q

Liver disease

general

A

PT (INR) more prolonged than aPTT

Distinguished from simple vitamin K deficiency by failure to respond to vitamin K replacement

Structural manifestations of liver disease contribute to bleeding
Portal hypertension
Esophageal varices
Gastritis
Hemorrhoids

53
Q

Mechanisms of Vitamin K deficiency

A

Nutritional depletion
Alcoholics
Long-term IV nutrition
Antibiotic administration
Interfere with bacteria synthesis and absorption
Warfarin

54
Q

Massive Transfusion

General

A

Defined as transfusion of more than 1.5 times the patient’s blood volume in 24 h
Acquired coagulopathy results from dilution of plasma and platelets and excess anticoagulant
10% of transfusion is anticoagulant

Prevention:
Administer 1-unit FFP and calcium chloride for every 4-6 units PRBC’s

55
Q

Hemophilia Therapy

Desmopressin (DDAVP)

A

MOA: Synthetic analogue of the antidiuretic hormone arginine vasopressin. In a dose dependent manner, desmopressin increases cyclic adenosine monophosphate (cAMP) in renal tubular cells which increases water permeability resulting in decreased urine volume and increased urine osmolality; increases plasma levels of von Willebrand factor, factor VIII, and t-PA contributing to a shortened activated partial thromboplastin time (aPTT) and bleeding time.

Use: DI, Hyponatremia, Hemophilia A, ICH 2’ to antiplatelet agents, vWD
Avoid in moderate to severe renal impairment
Dosage forms: Intranasal, Inj/Infusion, Tablet
Adverse effects: Hyponatremia, xerostomia, fluid retention

56
Q

Emicizumab (Hemlibra)

A

MOA: A humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific factor IXa- and factor X-directed antibody, bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis.

Use: Hemophilia A prophylaxis to prevent or reduce the frequency of bleeding episodes with or without factor VIII inhibitors
Initial: 3 mg/kg once weekly for 4 weeks
Maintenance: 1.5 mg/kg once weekly or 3 mg/kg once every 2 weeks or 6 mg/kg once every 4 weeks
Adverse effects: injection site reaction, headache, arthralgia
Avoid in pregnancy (lack of studies)

57
Q

Hematopoietic Stem Cell Transplant (HSCT)

A

Potentially curative treatment option for multiple malignant and benign diseases
Also known as bone marrow transplant
Patient receives healthy (unaffected) stem cells to replace their own

58
Q

Types of Hematopoietic Stem Cell Transplant (HSCT)

A

Autologous (patient’s own cells)

Allogeneic
cells from another person
Sibling
Parent or relative
Unrelated Donor
Source
Umbilical cord
Peripheral blood
Bone marrow

59
Q

indications for AUTOlogous stem cell transplant

A
60
Q

indications for allogenic transplant

A
61
Q

HSCT Process

A

1.Conditioning
2.Stem cell infusion
3. Neutropenic phase
4. Engraftment phase
5. Post-engraftment period

62
Q

Graft versus Host Disease (GVHD)

A

If donor cells see the host cells as foreign, they will attack the host
Skin, gut, and liver most likely to be affected
Acute < 100 days after the transplant
Chronic > 100 days

63
Q
A

CMT-dos (95 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions